Coenzyme Q10 ( DrugBank: Coenzyme Q10 )


12 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症1
5進行性核上性麻痺4
6パーキンソン病4
8ハンチントン病2
10シャルコー・マリー・トゥース病1
18脊髄小脳変性症(多系統萎縮症を除く。)1
46悪性関節リウマチ1
57特発性拡張型心筋症1
113筋ジストロフィー3
193プラダー・ウィリ症候群1
214心室中隔欠損を伴う肺動脈閉鎖症1
215ファロー四徴症1

2. 筋萎縮性側索硬化症


臨床試験数 : 624 薬物数 : 623 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00243932
(ClinicalTrials.gov)
April 200524/10/2005Clinical Trial of High Dose CoQ10 in ALSClinical Trial of High Dose CoQ10 in ALSAmyotrophic Lateral Sclerosis;Lou Gehrig's DiseaseDrug: coenzyme Q10;Drug: PlaceboColumbia UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Completed21 Years85 YearsAll185Phase 2United States

5. 進行性核上性麻痺


臨床試験数 : 95 薬物数 : 120 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00382824
(ClinicalTrials.gov)
September 200628/9/2006Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind StudyProgressive Supranuclear PalsyDietary Supplement: Coenzyme Q10;Other: PlaceboLahey ClinicNULLCompleted30 YearsN/AAll61N/AUnited States
2NCT00328874
(ClinicalTrials.gov)
May 200621/5/2006Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear PalsyMono-center, Prospective, Double-blind, Placebo-controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Coenzyme Q10German Parkinson Study Group (GPS)MSE Pharmazeutika GmbH, Louisenstr.114D-61348 Bad Homburg, Germany;Pitzer Stiftung;Philipps University Marburg Medical CenterCompleted40 Years85 YearsAll20Phase 2Germany
3EUCTR2005-000574-40-DE
(EUCTR)
24/04/200624/01/2006Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/ABrain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/A PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 100000 and an age-adjusted prevalence of 6.4 / 100000, PSP is as common as motor-neuron disease. The progression of PSP is rapid and the median survival after onset of symptoms is 5-10 years. Presently, there is no known effective symptomatic or neuroprotective therapy for PSP.Product Name: Coenzym Q10 Nanodispersion
Product Code: ASK Nr. 21972
INN or Proposed INN: Ubidecarenon
Other descriptive name: Coenzym Q10, Ubiquinon, Ubichinon
Kompetenznetz Parkinson e.V.NULLNot RecruitingFemale: yes
Male: yes
30Germany
4NCT00532571
(ClinicalTrials.gov)
January 200418/9/2007Effects of Coenzyme Q10 in PSP and CBDEffects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot StudyProgressive Supranuclear Palsy;Neurological DisordersDrug: CoQ10Lahey ClinicNULLCompleted40 YearsN/AAllPhase 2/Phase 3United States

6. パーキンソン病


臨床試験数 : 2,298 薬物数 : 2,218 - (DrugBank : 350) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01892176
(ClinicalTrials.gov)
June 201230/6/2013Effects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson DiseaseEffects of High-dose Coenzyme Q10 on Biomarkers of Oxidative Damage and Clinical Outcome in Parkinson DiseaseParkinson DiseaseDietary Supplement: coenzyme q10National University Hospital, SingaporeNULLCompleted21 MonthsN/ABoth20Phase 2/Phase 3Singapore
2NCT00740714
(ClinicalTrials.gov)
December 200822/8/2008Effects of Coenzyme Q10 (CoQ) in Parkinson DiseaseEffects of Coenzyme Q10 in Parkinson Disease - Phase IIIParkinson DiseaseDrug: Coenzyme Q10 with vitamin E;Drug: placebo with vitamin EWeill Medical College of Cornell UniversityNational Institute of Neurological Disorders and Stroke (NINDS);University of RochesterTerminated30 YearsN/AAll600Phase 3United States;Canada
3NCT00180037
(ClinicalTrials.gov)
September 20039/9/2005Coenzyme Q10 as a Symptomatic Treatment in Parkinson's DiseaseMulticenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's DiseaseParkinson's DiseaseDrug: Coenzyme Q10 Nanodispersion (Nanoquinone);Drug: PlaceboTechnische Universität DresdenDeutsche Parkinson-Vereinigung e.V.;MSE Pharmazeutika GmbH, Bad HomburgCompleted40 Years75 YearsBoth132Phase 3Germany
4NCT00004731
(ClinicalTrials.gov)
September 199825/2/2000Parkinson's Disease Treatment With Coenzyme Q10Effects of Coenzyme Q10 in Early Parkinson's DiseaseParkinson's DiseaseDrug: Coenzyme Q10National Institute of Neurological Disorders and Stroke (NINDS)NULLCompleted30 YearsN/ABothPhase 2United States

8. ハンチントン病


臨床試験数 : 229 薬物数 : 197 - (DrugBank : 60) / 標的遺伝子数 : 84 - 標的パスウェイ数 : 158
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00920699
(ClinicalTrials.gov)
February 20109/6/2009Study in PRE-manifest Huntington's Disease of Coenzyme Q10 (UbiquinonE) Leading to Preventive Trials (PREQUEL)A Multi-Center, Double-Blind, Randomized, Parallel Group Tolerability Study of Coenzyme Q10 (UbiquinonE)in PRE-manifest Huntington's DiseaseHuntington's DiseaseDrug: CoQ10Johns Hopkins UniversityNational Institute of Neurological Disorders and Stroke (NINDS)Completed18 YearsN/AAll90Phase 2United States
2NCT00608881
(ClinicalTrials.gov)
March 20084/2/2008Coenzyme Q10 in Huntington's Disease (HD)Coenzyme Q10 in Huntington's Disease (HD)Huntington's DiseaseDrug: coenzyme Q10;Other: placeboMassachusetts General HospitalNational Institute of Neurological Disorders and Stroke (NINDS);University of RochesterTerminated16 YearsN/AAll609Phase 3United States;Australia;Canada

10. シャルコー・マリー・トゥース病


臨床試験数 : 39 薬物数 : 45 - (DrugBank : 9) / 標的遺伝子数 : 11 - 標的パスウェイ数 : 15
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00541164
(ClinicalTrials.gov)
September 20079/10/2007Effects of Coenzyme Q10 on Charcot-Marie-Tooth DiseaseEffects of Coenzyme Q10 (CoQ10) on Subjects With Charcot-Marie-Tooth Disease (CMT):A Double Blind, Randomized, Controlled Trial With an Open Label Follow-up StudyCharcot Marie Tooth DiseaseDrug: Coenzyme Q10;Dietary Supplement: Coenzyme Q10Memorial Medical CenterDepartment of DefenseCompleted18 Years75 YearsBoth23Phase 1/Phase 2United States

18. 脊髄小脳変性症(多系統萎縮症を除く。)


臨床試験数 : 71 薬物数 : 101 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1JPRN-UMIN000031788
2018/06/0101/04/2018coenzymeQ10 for Autosomal recessive spinocerebellar ataxia type II Autosomal recessive spinocerebellar ataxia type IIhigh dose of coenzyme Q10Department of Neurology, Tokushima University, JapanNULLComplete: follow-up complete50years-old100years-oldMale and Female1Not selectedJapan

46. 悪性関節リウマチ


臨床試験数 : 4,325 薬物数 : 2,681 - (DrugBank : 417) / 標的遺伝子数 : 185 - 標的パスウェイ数 : 223
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR-IPR-17010325
2017-01-312017-01-04The efficacy and safety of Metformin combined with coenzyme Q10 in refractory rheumatoid arthritis: A multi-center randomized controlled trialThe efficacy and safety of Metformin combined with coenzyme Q10 in refractory rheumatoid arthritis: A multi-center randomized controlled trial rheumatic disease;M05.901Metformin Group:Metformin combined Glucocorticoids and DMARDs;Non-Metformin Group:Glucocorticoids and DMARDs;Metformin combined with Coenzyme Q10 Group:Metformin and Coenzyme Q10 combined Glucocorticoids and DMARDs;the Second Hospital of Shanxi Medical UniversityNULLPending1865BothMetformin Group:100;Non-Metformin Group:100;Metformin combined with Coenzyme Q10 Group:100;China

57. 特発性拡張型心筋症


臨床試験数 : 12 薬物数 : 25 - (DrugBank : 12) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 34
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02115581
(ClinicalTrials.gov)
September 200622/12/2008Coenzyme Q10 Supplementation in Children With Idiopathic Dilated CardiomyopathyEffect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical TrialDilated CardiomyopathyDrug: Coenzyme Q10;Drug: PlaceboUniversity of TehranNULLCompleted6 Months18 YearsAll38Phase 4Iran, Islamic Republic of

113. 筋ジストロフィー


臨床試験数 : 622 薬物数 : 494 - (DrugBank : 99) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 168
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01126697
(ClinicalTrials.gov)
February 201018/5/2010Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular DystrophiesPITT0908: Clinical Trial of Coenzyme Q10 and Lisinopril in Muscular DystrophiesDuchenne Muscular Dystrophy;Becker Muscular Dystrophy;Limb Girdle Muscular DystrophyDrug: Coenzyme Q10 and LisinoprilCooperative International Neuromuscular Research GroupUnited States Department of DefenseCompleted8 YearsN/AAll63Phase 2/Phase 3United States;Canada;Japan
2NCT00308113
(ClinicalTrials.gov)
April 200727/3/2006CoQ10 and Prednisone in Non-Ambulatory DMDPITT0503: Clinical Trial of Coenzyme Q10 and Prednisone in Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: Prednisone;Dietary Supplement: Coenzyme Q10Cooperative International Neuromuscular Research GroupUnited States Department of DefenseTerminated10 Years18 YearsMale3Phase 3United States;Australia;Puerto Rico
3NCT00033189
(ClinicalTrials.gov)
September 20018/4/2002An Open-label Pilot Study of Coenzyme Q10 in Steroid-Treated Duchenne Muscular DystrophyMuscular Dystrophy, DuchenneDrug: Coenzyme Q10Cooperative International Neuromuscular Research GroupNULLCompleted5 Years11 YearsMale15Phase 2United States

193. プラダー・ウィリ症候群


臨床試験数 : 111 薬物数 : 122 - (DrugBank : 30) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 103
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03831425
(ClinicalTrials.gov)
May 1, 202222/1/2019Mitochondrial Complex I Dysfunction in PWSMitochondrial Complex I Dysfunction in Prader Willi Syndrome: A New Therapeutic TargetPrader-Willi SyndromeDietary Supplement: Coenzyme Q10;Other: PlaceboThe Hospital for Sick ChildrenFoundation for Prader-Willi ResearchRecruiting13 Years18 YearsAll14Phase 2Canada

214. 心室中隔欠損を伴う肺動脈閉鎖症


臨床試験数 : 2 薬物数 : 4 - (DrugBank : 4) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR1900025513
2019-09-012019-08-31The safety and efficacy of preoperative oral supplementation of coenzyme Q10 in improving postoperative cardiac function in children with tetralogy of fallot (pulmonary atresia): a preliminary studyThe safety and efficacy of preoperative oral supplementation of coenzyme Q10 in improving postoperative cardiac function in children with tetralogy of fallot (pulmonary atresia): a preliminary study tetralogy of fallot (pulmonary atresia)01:N/A ;02:Oral coenzyme Q10, 2.5mg, t.i.d.;03:Oral coenzyme Q10, 5mg, t.i.d.;04:Oral coenzyme Q10, 10mg, t.i.d.;05:Oral coenzyme Q10, 20mg, t.i.d.;Fuwai Central China Cardiovascualr HospitalNULLPending02Both01:8;02:8;03:8;04:8;05:8;China

215. ファロー四徴症


臨床試験数 : 22 薬物数 : 48 - (DrugBank : 19) / 標的遺伝子数 : 18 - 標的パスウェイ数 : 49
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR1900025513
2019-09-012019-08-31The safety and efficacy of preoperative oral supplementation of coenzyme Q10 in improving postoperative cardiac function in children with tetralogy of fallot (pulmonary atresia): a preliminary studyThe safety and efficacy of preoperative oral supplementation of coenzyme Q10 in improving postoperative cardiac function in children with tetralogy of fallot (pulmonary atresia): a preliminary study tetralogy of fallot (pulmonary atresia)01:N/A ;02:Oral coenzyme Q10, 2.5mg, t.i.d.;03:Oral coenzyme Q10, 5mg, t.i.d.;04:Oral coenzyme Q10, 10mg, t.i.d.;05:Oral coenzyme Q10, 20mg, t.i.d.;Fuwai Central China Cardiovascualr HospitalNULLPending02Both01:8;02:8;03:8;04:8;05:8;China